Sigma Designs, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results

Expects 11-15 Percent Sequential Revenue Growth and Return to Profitability in Q1 FY14

Sigma Designs^®, Inc. ( NASDAQ : SIGM ), a leader in connected media platforms, today reported financial results and business highlights for its fourth fiscal quarter and fiscal year ended February 2, 2013.

Net revenue for fiscal year 2013 was $216.6 million, an increase of $34.0 million, or 18.6%, from $182.6 million in the previous year. Net revenue for the fourth quarter of fiscal 2013 was $44.2 million, down $19.7 million, or 31.0%, from $63.9 million reported in the previous quarter and up $8.6 million, or 24.0%, from $35.6 million reported for the same period last year.

Opsens signs first major agreement in the medical field granting distribution rights of its FFR products for Japan, Korea and Taiwan in US$5 million transaction

Opsens Inc. ("Opsens") (OPS.V) is pleased to announce its first major agreement granting distribution and other rights for its OptoWire and OptoMonitor, Opsens' products for measuring Fractional Flow Reserve ("FFR").

Under the terms of the agreement with a Japanese-based medical company, Opsens will receive:

• US$3 M for the distribution rights for its FFR products for Japan , Korea and Taiwan , which includes:

  Published: 19 November 2012

  Written by Editor

  TSX Venture   High Tech   Project Updates   Up on News   Interesting News  

  Read more: Opsens Inc ( OPS )

Bruker Reports Financial Results for the Third Quarter of 2012

Bruker Corporation (BRKR) today reported financial results for the third quarter ended September 30, 2012.

Bruker Corporation Financial Results
In the third quarter of 2012, revenue was $447.8 million, an increase of 7.0% compared to $418.4 million in the third quarter of 2011. Excluding the effects of acquisitions and foreign currency translation, third quarter 2012 revenue increased by 13.8% year-over-year. GAAP net income for the third quarter of 2012 was $39.7 million, or $0.24 per diluted share, compared to $19.8 million, or $0.12 per diluted share, in the third quarter of 2011. Adjusted net income for the third quarter of 2012 was $47.1 million, or $0.28 per diluted share, compared to $34.4 million, or $0.21 per diluted share, in the third quarter of 2011.

IRIS International Announces Agreement to be Acquired by Danaher Corporation for $19.50 per Share

IRIS International, Inc. (IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a provider of high value personalized medicine solutions, today announced that it has entered into a definitive merger agreement under which Danaher Corporation (DHR) will acquire IRIS International for $19.50 per share in cash, representing an approximate 45% premium over the closing price of IRIS's common stock on September 14, 2012.

An affiliate of Danaher is expected to commence a tender offer for all of IRIS's outstanding common stock within the next 7 days, which offer will remain open for a minimum of 20 business days following its commencement. The tender offer is conditioned upon at least a majority of IRIS' outstanding shares being tendered, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions